Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.
Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a variety of malignancies. Therefore, this review catalogs recent advances in natural product-based drug discovery via the examination of mechanisms of action and available clinical data to highlight the utility of these novel compounds in the burgeoning age of precision medicine. The review also highlights the recent development of antibody-drug conjugates and other immunotoxins, which are capable of delivering highly cytotoxic agents previously deemed too toxic to elicit therapeutic benefit preferentially to neoplastic cells. Finally, the review examines natural products not currently used in the clinic that have novel mechanisms of action, and may serve to supplement current chemotherapeutic protocols.
Department of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA. mrtrendo@syr.edu.
Matthew
M
Trendowski
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001688:Biological Products / Q000494:pharmacology* / Q000627:therapeutic use*; D003572:Cytochalasins / Q000494:pharmacology / Q000627:therapeutic use; D004149:Dioxoles / Q000494:pharmacology / Q000627:therapeutic use; D004167:Diphtheria Toxin / Q000494:pharmacology / Q000627:therapeutic use; D055808:Drug Discovery / Q000379:methods*; D034261:Epothilones / Q000494:pharmacology / Q000627:therapeutic use; D005663:Furans / Q000494:pharmacology / Q000627:therapeutic use; D006248:Harringtonines / Q000494:pharmacology / Q000627:therapeutic use; D000077863:Homoharringtonine; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use; D007659:Ketones / Q000494:pharmacology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D044005:Tetrahydroisoquinolines / Q000494:pharmacology / Q000627:therapeutic use; D000077606:Trabectedin; D054358:Withanolides / Q000494:pharmacology / Q000627:therapeutic use; D000095662:Polyether Polyketides
D000970:Antineoplastic Agents; D001688:Biological Products; D003572:Cytochalasins; D004149:Dioxoles; D004167:Diphtheria Toxin; D034261:Epothilones; D005663:Furans; D006248:Harringtonines; D000077863:Homoharringtonine; D018796:Immunoconjugates; D007376:Interleukin-2; D007659:Ketones; D011993:Recombinant Fusion Proteins; D058570:TOR Serine-Threonine Kinases; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin; D054358:Withanolides; C078456:denileukin diftitox; C546842:MTOR protein, human; C490954:eribulin; D000095662:Polyether Polyketides